Oxytocin 10u/mL

Route: Intramuscular (IM) or intravenous (IV) injection.

• IV infusion: Must be diluted in a compatible IV solution (e.g., 0.9% NaCl or D5W) and administered via infusion pump with continuous monitoring by trained personnel.
• IM injection: Administered as a single dose into a large muscle (e.g., deltoid or thigh); rotate injection sites if multiple doses are required.
• Inspect solution for particulate matter and discoloration prior to administration. Do not use if discolored or cloudy.

Dosing is entirely prescriber-determined and indication-specific. Standardized institutional protocols are recommended to minimize errors. General reference ranges from FDA labeling include:

• Labor induction/augmentation: 0.5–2 mIU/min IV initially, titrated by 1–2 mIU/min every 15–40 min; usual effective range 6 mIU/min.
• Postpartum uterine atony (prophylaxis): 10 units IM following placental delivery.
• Postpartum hemorrhage (therapeutic): 10–40 units added to 1,000 mL IV fluid, rate adjusted to control atony.
• Oxytocin does not follow a predictable dose-response; clinical monitoring of uterine activity and fetal heart rate is essential.

All dosing decisions rest with the prescribing clinician.

• Oxytocin: Binds to G protein-coupled oxytocin receptors (OTRs) on uterine myometrium, activating phospholipase C, increasing intracellular calcium, and triggering actin-myosin cross-bridge cycling to produce uterine contractions. At the mammary gland, OTR activation contracts myoepithelial cells to induce milk ejection. Exogenous oxytocin has an elimination half-life of 1–6 minutes and is metabolized primarily in the liver and plasma by oxytocinase.

Indications context: Synthetic oxytocin is used in obstetric settings for induction and augmentation of labor at or near term when medically indicated, management of postpartum hemorrhage, and adjunctive treatment of inevitable or incomplete abortion. It is also being investigated in compounded intranasal formulations for social/behavioral applications (see separate entry), but the 10 u/mL injectable concentration is an obstetric preparation.

Monitoring:

• Continuous electronic fetal monitoring and uterine activity assessment during IV infusion.
• Fluid balance monitoring—oxytocin has antidiuretic properties at high cumulative doses; restrict oral fluid intake to reduce risk of water intoxication.
• Vital signs, uterine tone, and fetal heart rate at defined intervals per institutional protocol.
• Magnesium sulfate should be immediately available for uterine relaxation if hyperstimulation occurs.

Contraindications:

• Hypersensitivity to oxytocin or any component of the formulation.
• Conditions where vaginal delivery is contraindicated (e.g., vasa previa, active genital herpes, prior classical uterine incision, umbilical cord prolapse).
• Fetal distress where delivery is not imminent.
• Elective induction of labor when fetal maturity is not established.

Warnings & Precautions:

• Uterine hyperstimulation, hypertonia, tetanic contractions, and uterine rupture—discontinue infusion immediately if hyperstimulation occurs.
• Water intoxication with hyponatremia, seizures, coma, and death reported with prolonged high-dose infusion; restrict oral fluid intake.
• Severe maternal hypotension when combined with caudal block anesthesia and vasopressors.
• Cardiovascular effects: tachycardia, arrhythmias, and myocardial ischemia at supratherapeutic doses.
• Use only in settings with qualified personnel capable of managing obstetric complications; have resuscitative equipment available.

Drug Interactions:

• Vasoconstrictors (e.g., ephedrine, phenylephrine with regional anesthesia): risk of severe hypertension.
• Prostaglandins (e.g., dinoprostone): allow a minimum 6–12-hour interval before oxytocin initiation after cervical gel, or 30 minutes after dinoprostone insert removal.
• Tranexamic acid (IV): may significantly reduce oxytocin plasma concentrations when co-administered intravenously; avoid mixing in same line.

Common Side Effects: Nausea, vomiting, injection site erythema, intensification of uterine contractions; with higher doses—fetal bradycardia, maternal hypotension, antidiuresis.

Store at controlled room temperature (15–25°C / 59–77°F). Do not freeze. Protect from light. Use within the beyond-use date assigned by Genesis Compounding per USP <797> standards. Discard any unused portion of diluted IV solutions promptly after infusion. Do not use if the solution is discolored or contains particulate matter.

What is this medication used for?

Oxytocin 10 u/mL injection is used under prescriber direction in obstetric settings for induction or augmentation of labor, control of postpartum uterine bleeding, and management of incomplete abortion. It must be administered by trained clinical personnel with appropriate monitoring equipment available.

How is this medication administered?

It is given either as an intravenous infusion (diluted in a compatible IV solution and controlled by infusion pump) or as an intramuscular injection. The intravenous route is preferred for labor induction because it allows precise dose titration and rapid dose adjustment.

Is this the same as the natural hormone?

Synthetic oxytocin is structurally identical to the endogenous nonapeptide produced in the hypothalamus and released by the posterior pituitary. Compounded oxytocin is not an FDA-approved commercial product; it is prepared by Genesis Compounding as a patient-specific 503A preparation under a valid prescriber order.

What monitoring is required?

Continuous uterine activity and fetal heart rate monitoring are required during IV infusion. Fluid balance, maternal vital signs, and uterine tone must be assessed at regular intervals. Facilities for emergency obstetric intervention must be immediately available.

How should unused portions be handled?

Any unused or residual solution should be discarded immediately after the infusion is discontinued. Do not save or reuse opened vials. Dispose of needles and syringes in an appropriate sharps container.